New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.
Genomic analysis in IO trials is on the increase - what happens when PD-1 and KRAS collide?
A look at several different innate immune system approaches
New developments in the DDR niche suggest a whole new approach to tackling solid tumours beyond women's cancers, pancreatic and prostate cancer might be feasible.
An expert interview with a leading immunologist who discusses two translational opportunities with potential for cancer immunotherapy
What can we learn from recent trial data exploring a STING agonist in combination with anti-PD-1 in advanced solid tumors including TNBC & melanoma?
Targeting STING in cancer with a systemic small molecule approach? What's the story?
What does a next generation STING agonist look like and what issues is it attempting to address?
An in-depth look at the growing STING R&D landscape in oncology
Highlights from the AACR special conference on tumour immunology and immunotherapy
There are a number of important lessons we can learn from early phase 1 trials. Here are some of them.
ESMO18 Preview 1 - Late Breaking Abstracts to watch out for
Expert interview with Dr Glen Barber reignites the controversy over whether STING agonists could cause metastasis in cancer patients.
Can STING agonists promote cancer metastasis in some patients? That's one of the key questions from new research linking chromosomal instability with tumor metastasis through activation of the cGAS-STING pathway.
A candid look at new approaches being explored in cold tumours using prostate cancer as an example
How do we overcome resistance to cancer immunotherapies? Here, we have an in-depth interview with a thought leader in this space.
Can we safely combine a STING agonist with a checkpoint inhibitor to generate more effectiveness in melanoma and lymphomas?
We asked experts at AACR what they really thought...
Dr Tom Gajewski is working on STING agonists that may have a major role to play in cancer immunotherapy.
Novartis have announced a deal with Aduro Biotech for access to their STING-targeted CDN platform technology.